Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors

NESS ZIONA, Israel, June 28, 2018 -- (Healthcare Sales & Marketing Network) -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of M-001, a clinical phase Universal Influenza Vaccine candidate, announced today the appointment of Mr. Mark Germain a... Biopharmaceuticals, Personnel BiondVax Pharmaceuticals, influenza, influenza vaccine, flu vaccine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news